Page 19 - 16_2021_49-66
P. 19

  9. Da Ros L, Recchia G, Gussoni G. (2021). Perché un volume sul- le Terapie Digitali per l’Italia. Tendenze nuove. Milano: Passoni Editore; 2021.
10. Ravot E, Ascione R. Modalità di accesso/rimborsabilità per le terapie digitali già attive in altri sistemi sanitari. Tendenze nuove. Milano: Passoni Editore; 2020.
11. Morin CM. Profile of Somryst Prescription Digital Thera- peutic for Chronic Insomnia: Overview of Safety and Effica- cy. Expert Review of medical devices. 2020(17):1239–1248 doi: 10.1080/17434440.2020.1852929.
12. Sampson C, Bell E, Cole A, Miller CB, Rose J. Digital cogni- tive behavioural therapy for insomnia and primary care costs in England: an interrupted time series analysis. 2021. doi: 10.1101/2021.02.15.21249646.
13. Freeman D, Sheaves B, Goodwin GM, et al. The effects of im- proving sleep on mental health (OASIS): a randomised con- trolled trial with mediation analysis. The Lancet Psychiatry. 2017;4:749–58. doi: 10.1016/S2215-0366(17)30328-0.
14. Espie CA, Kyle SD, Williams C, et al (2012). A Randomised, Pla- cebo-Controlled Trial of Online Cognitive Behavioral Therapy for Chronic Insomnia Disorder Delivered via an Automated Me- dia-Rich Web Application. Sleep. 2012(35),769–81. doi: 10.5665/ sleep.1872.
15. Luik A, Marsden A, Emsley R, et al. Long-term benefits of digital cognitive behavioural therapy for insomnia: Follow-up report from a randomised clinical trial. Journal of Sleep Research. 2020 (29). doi: 10.1111/jsr.13018.
16. Dang A, Dang D, Rane P. The Expanding Role of Digital Thera- peutics in the Post-COVID-19. The open Covid Journal. 2021.
17. Valutazione degli indicatori di qualità dell’assistenza al diabete in Italia. Annalis AMD. Annali 2018. https://aemmedi.it/anna- li-amd/ Ultimo accesso: novembre 2021.
18. Kvedar J C, Fogel AL, Elenko E, Zohar D. Digital medicine’s march on chronic disease. Nature Biotechnology. 2016:34.
19. Cafazzo A. A Digital-First Model of Diabetes Care. Emerging dig- ital health technologies in diabetes. 2019:21. Supplement 2. doi: 10.1089/dia.2019.0058.
20. Kikuchi S, Kadama K, Sengoku S. Characteristics and Classifi- cation of Technology Sector Companies in Digital Health for Di- abetes. Sustainability 2021;13(9), 4839. doi: 10.3390/su13094839.
21. Kaufman N, Ferrin C, Sugrue D. Using Digital Health Technology to Prevent and Treat Diabetes. Diabetes Technology & Therapeu- tics. 2019:79-94. doi: 10.1089/dia.2019.2506.
22. Martini N, Calabria S, Recchia G, Gussoni G, Ciani O. Terapie di- gitali, HTA e rimborso in Italia. Tendenze nuove. Milano: Passoni Editore; 2021.
23. Quinn C, Swasey K, Christopher J, Crabbe F, Shardell M, Ter-
rin M, Barr E, Gruber- Baldini A. The impact of a mobile dia- betes health intervention on diabetes distress and depression among adults: secondary analysis of a cluster randomized controlled trial. JMIR Mhealth Uhealth. 2017;5(12). doi: 10.2196/ mhealth.8910.
24. Sabate E. WHO Adherence Meeting Report. Geneva: World Health Organization; 2001.
25. La spesa farmaceutica nel 2019. Analisi dell’andamento della spe- sa farmaceutica convenzionata a livello nazionale e regionale. Fe- derfarma. Giugno 2020. https://www.federfarma.it/Documen- ti/spesa/2019/Spesa2019.aspx Ultimo accesso: novembre 2021.
26. Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei far- maci in Italia. Rapporto Nazionale 2020. Roma: Agenzia Italiana del Farmaco, 2021.
27. Kamat T. Digital therapeutics can improve medication adhe- rence in diabetes. Journal of Family Medical Primary Care. 2020;9(11):5806-5807. doi: 10.4103/ jfmpc.jfmpc_1252_20.
28.Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
29. Patel NA, Butte AJ. Characteristics and challenges of the clin- ical pipeline of digital therapeutics. NPJ Digital Medicine;3,159. doi: 10.1038/s41746-020-00370-8.
30.Pizzini A. L’aderenza terapeutica nella pratica clinica. Clinical Management Issues. 2008.
31. Nieuwlaat et al. Interventions for enhancing medication ad- herence (Review). 2014 Cochrane Database of Systematic Re- views. 2014 Nov; 20;2014(11):CD000011. doi: 10.1002/14651858. CD000011.pub4.
32. Basili S, Raparelli V, Camgemi R, Lenzi A. (2016). L’aderenza alla terapia in medicina Il problema, i modelli, cosa insegnare agli Studenti e quando. Medicina & Chirurgia. 2016;70:3173-3175.
33. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J et al. A meta-analysis of the association between ad- herence to drug therapy and mortality. BMJ. 2006;333:15-20.
34.Position Paper on the definition of Pharmaceutical Care 2013. Pharmaceutical Care Network Europe. 2013. https://www.pcne. org/upload/files/3_PCNE_Definition_Position_Paper_final.pdf Ultimo accesso: novembre 2021.
35.Evans SW, Beauchaine TP, Chronis-Tuscano A, Becker SP, Chacko E, Gallagher R, Hartung CM, Kofler MJ, Schultz BK, Tamm L, Youngstrom EA. The Efficacy of Cognitive Videogame Training for ADHD and What FDA Clearance Means for Clini- cians. Evidence-based practice in child and adolescent mental health. 2021. Vol. 6.
36. The Digital Economy and Society Index (DESI) 2020. Commissione Europea – Agenzia per l’Italia Digitale; PNRR.
G.L. Colombo et al. / CLINICO ECONOMICS ITALIAN ARTICLES ON OUTCOMES RESEARCH / VOL 16 / ANNO 2021 / PAG. 49-66 65





































































   16   17   18   19   20